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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Algerian Arabic 
language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical vali-
dation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 70 JIA patients (10.0% systemic, 35.7.0% oligoarticular, 21.4% RF nega-
tive polyarthritis, 32.9% other categories) and 70 healthy children, were enrolled in a paediatric rheumatology centre. The 
JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory 
psychometric performances. In conclusion, the Algerian Arabic version of the JAMAR is a valid tool for the assessment of 
children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Algerian Arabic parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
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arthritis (JIA). The JAMAR assesses the most relevant 
parent/patient-reported outcomes in JIA, including overall 
well-being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Algerian Arabic language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from December 2012 
to April 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 (1) Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored: 0 = without difficulty, 1 = with some diffi-
culty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the 
question or the patient was unable to perform the task 
due to their young age or to reasons other than JIA. 
The total PF score ranges from 0 to 45 and has three 
components: PF-lower limbs (PF-LL); PF-hand and 
wrist (PF-HW) and PF-upper segment (PF-US) each 
scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 (2) Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11];
 (3) Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 (4) Assessment of morning stiffness (present/absent);
 (5) Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 (6) Rating of the level of disease activity on a 21-circle 
VAS;
 (7) Rating of disease status at the time of the visit (cat-
egorical scale);
 (8) Rating of disease course from previous visit (categori-
cal scale);
 (9) Checklist of the medications the patient is taking (list 
of choices);
 (10) Checklist of side effects of medications;
 (11) Report of difficulties with medication administration 
(list of items);
 (12) Report of school/university/work problems caused by 
the disease (list of items);
 (13) Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the 
time’ (score = 2) and ‘all the time’ (score = 3). A ‘not 
assessable’ column was included in the parent version 
of the questionnaire to designate questions that cannot 
be answered because of developmental immaturity. 
The total HRQoL score ranges from 0 to 30, with 
higher scores indicating worse HRQoL. A separate 
score for PhH and PsH (range 0–15) can be calculated 
[12–14];
 (14) Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 (15) A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. The Alge-
rian Arabic version is the result of the local adaptation of 
the translation in Arabic performed by the PRINTO centre in 
Saudi Arabia. Reading, comprehension and understanding of 
the translated questionnaires were tested in a probe sample 
of ten JIA parents and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
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The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproduc-
ibility of the JAMAR repeated after 1 or 2 weeks); and 
construct validity in its two components: the convergent 
or external validity which examines the correlation of the 
JAMAR subscales with the six JIA core set of variables, 
with the addition of the parent assessment of disease activity 
and pain by the Spearman’s correlation coefficients (r) [17] 
and the discriminant validity, which assesses whether the 
JAMAR discriminates between the different JIA categories 
and healthy children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Algerian Arabic parent and patient versions 
of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Algerian Arabic JAMAR was fully cross-culturally 
adapted from the Arabic version performed by the PRINTO 
centre in Saudi Arabia with no forward and backward 
translation.
All the 123 lines in the parent version of the JAMAR 
were understood by at least 80% of the ten parents tested 
(median = 100%; range 80–100%); all the 120 lines in the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 90–100%).
Demographic and clinical characteristics 
of the subjects
A total of 70 JIA patients and 70 healthy children (total of 
140 subjects) were enrolled at the paediatric rheumatology 
centre of Alger.
In the JIA subjects, the JIA categories were 10.0% with 
systemic arthritis, 35.7% with oligoarthritis, 21.4% with RF 
negative polyarthritis, 20.0% with RF-positive polyarthri-
tis, 1.4% with psoriatic arthritis and 11.4% with enthesitis-
related arthritis. Notably, none of the enrolled JIA patients 
is affected with undifferentiated arthritis (Table 1).
All the 140 enrolled subjects had the parent version of 
the JAMAR completed by a parent (70 from parents of 
JIA patients and 70 from parents of healthy children). The 
JAMAR was completed by 90/140 (64.3%) mothers and 
50/140 (35.7%) fathers. The child version of the JAMAR 
was completed by all the 140 children enrolled, age 5.7 or 
older. In addition, patients younger than 7 years old, capable 
to assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 4.3% (1.4–8.6%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different PF 
items and for the HRQoL items except for item 15 and item 
2, respectively.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 0% (0–0%) for the PF and 1.5% (1–2.0%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 67.1% (62.9–74.3%) for the 
PF items, 35.7% (27.1–37.1%) for the HRQoL PhH items, 
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and 45.7% (38.6–47.1%) for the HRQoL PsH items. The 
median ceiling effect was 2.9% (1.4–4.3%) for the PF items, 
8.6% (2.9–10.0%) for the HRQoL PhH items, and 7.1% 
(2.9–7.1%) for the HRQoL PsH items. The median floor 
effect was 20.0% for the pain VAS, 21.4% for the disease 
activity VAS and 17.1% for the well-being VAS. The median 
Table 1  Descriptive statistics (medians, 1st, 3rd quartiles or absolute frequencies and %) for the 140 JIA patients
Data related to the JAMAR refers to the 70 JIA patients and to the 70 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS Visual Analogue 
Scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, ** p < 0.001, #p < 0.0001
Systemic N = 7 Oligoarthritis 
N = 25
RF− polyarthri-
tis N = 15
RF + polyarthri-
tis N = 14
Psoriatic arthri-
tis N = 1
Enthesitis-
related arthritis 
N = 8
All JIA patients 
N = 70
Healthy N = 70
Female 4 (57.1%) 18 (72%) 9 (60%) 13 (92.9%) 1 (100%) 0 (0%) 45 (64.3%)** 46 (65.7%)
Age at visit 11 (8.3–12.1) 12.4 (10.5–13) 11.4 (9.3–14.4) 14.9 (13.2–16.1) 17.2 (17.2–17.2) 15.4 (14.7–16) 12.7 (10.7–
14.9)**
12.7 (10.7–14.9)
Age at onset 3.8 (1.9–7.7) 5.1 (3.2–8.4) 7.2 (3.9–11.2) 10.8 (5.9–12.5) 9.3 (9.3–9.3) 12.2 (9.9–13) 7.3 (3.9–11)**
Disease duration 5.5 (4–7.8) 4.9 (3.6–8.7) 3.4 (1.8–6.6) 3.5 (2.2–5.7) 7.8 (7.8–7.8) 3.8 (1.9–5.1) 4.5 (2.5–6.8)
ESR 37.5 (17–75) 15.5 (10–46) 24 (5–66) 27 (15–53) 88 (88–88) 47.5 (24–63) 25 (12–56)
MD VAS 5 (5–9) 3 (1–5) 2 (1–3) 4 (2–6) 8 (8–8) 4.5 (3–6) 3 (1–5)
No. of swollen 
joints
2 (1–3) 1 (0–2) 1 (0–6) 2 (1–2) 8 (8–8) 0 (0–0.5) 1 (0–3)
No. of joints with 
pain
6 (2–17) 2 (0–3) 1 (0–2) 1 (0–4) 10 (10–10) 2.5 (1.5–3) 2 (0–3)
No. of joints with 
LOM
5 (2–19) 1 (0–3) 1 (0–2) 1.5 (0–4) 10 (10–10) 1 (0.5–2.5) 1 (0–3)
No. of active 
joints
8 (2–17) 1 (1–3) 2 (0–7) 2.5 (1–6) 10 (10–10) 1 (0.5–3) 2 (1–5)
Active systemic 
features
2 (28.6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2.9%)*
ANA status 0 (0%) 2 (8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2.9%)
Uveitis 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1/68 (1.5%)
PF total score 8 (0–18) 6 (3–9) 4 (0–10) 6 (1–9) 22 (22–22) 3.5 (1–11.5) 5 (1–12) 0 (0–0)#
Pain VAS 6 (0–9) 2 (1–5) 0 (0–5) 5 (0–5) 10 (10–10) 6 (4–7) 3 (0–6) 0 (0–0)#
Disease activity 
VAS
0 (0–1.5) 3 (0.5–5) 0 (0–4) 5 (2–6) 10 (10–10) 0 (0–7) 2 (0–5)
Well-being VAS 4 (0–9) 3 (0–5) 0 (0–4) 5 (5–6) 10 (10–10) 3 (2–3) 3.5 (0–5)
HRQoL PhH 7 (0–10) 4 (1–5) 3 (1–10) 5.5 (3–11) 12 (12–12) 4.5 (3–7) 5 (2–8) 0 (0–1)#
HRQoL PsH 9 (0–11) 3 (2–5) 2 (0–10) 3.5 (2–6) 99 (99–99) 3.5 (0–6.5) 3 (1–7) 0 (0–2)#
HRQoL total 
score
19 (1–21) 7 (3–10) 6 (3–20) 12.5 (7–18) 99 (99–99) 9 (4.5–12) 7 (4–15) 0 (0–4)#
Pain/swell. in > 1 
joint
5 (71.4%) 22 (88%) 9 (60%) 12 (85.7%) 1 (100%) 6 (75%) 55 (78.6%) 12 (17.1%)#
Morning stiff-
ness > 15 min
2/6 (33.3%) 8/24 (33.3%) 2/13 (15.4%) 6 (42.9%) 0 (0%) 2/7 (28.6%) 20/65 (30.8%) 2 (3.7%)**
Subjective remis-
sion
1 (14.3%) 15 (60%) 4/14 (28.6%) 10 (71.4%) 1 (100%) 3 (37.5%) 34/69 (49.3%)*
In treatment 5/6 (83.3%) 22/23 (95.7%) 14 (93.3%) 13 (92.9%) 1 (100%) 7 (100%) 62/66 (93.9%)
Reporting side 
effects
4/5 (80%) 12/22 (54.5%) 4/14 (28.6%) 4/12 (33.3%) 1 (100%) 4/7 (57.1%) 29/61 (47.5%)
Taking medica-
tion regularly
5/5 (100%) 18/22 (81.8%) 12/13 (92.3%) 11/13 (84.6%) 0 (0%) 6/7 (85.7%) 52/61 (85.2%)
With problems 
attending school
3/5 (60%) 6/20 (30%) 0 (0%) 6/10 (60%) 1 (100%) 3/7 (42.9%) 19/49 (38.8%) 3 (6.5%)**
Satisfied with dis-
ease outcome
4/6 (66.7%) 14/24 (58.3%) 9/13 (69.2%) 6 (42.9%) 1 (100%) 5 (62.5%) 39/66 (59.1%)
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ceiling effect was 1.4% for the pain VAS, 1.4% for the dis-
ease activity VAS and 4.3% for the well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson’s items–scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 100% 
of the PF items and for 100% of the HRQoL items.
Item internal consistency (third Likert assumption)
Pearson’s items–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 70 Child N = 70
Missing values (1st–3rd quartiles) 4.3 (1.4–8.6) 4.3 (1.4–5.7)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 67.1% 67.1%
 HRQoL PhH 35.7% 32.9%
 HRQoL PsH 45.7% 48.6%
 Pain VAS 20.0% 17.1%
 Disease activity VAS 21.4% 15.7%
 Well-being VAS 17.1% 17.1%
Ceiling effect, median
 PF 2.9% 1.4%
 HRQoL PhH 8.6% 7.1%
 HRQoL PsH 7.1% 7.1%
 Pain VAS 1.4% 0.0%
 Disease activity VAS 1.4% 0.0%
 Well-being VAS 4.3% 2.9%
Items with equivalent item–scale correlation 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Items with items–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.84 0.85
 PF-HW 0.92 0.92
 PF-US 0.88 0.92
 HRQoL PhH 0.91 0.90
 HRQoL PsH 0.91 0.90
Items with item–scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.97 0.57
 HRQoL PhH 0.99 1.00
 HRQoL PsH 1.00 0.95
Spearman’s correlation with JIA core set variables, median
 PF 0.6 0.6
 HRQoL PhH 0.6 0.5
 HRQoL PsH 0.3 0.3
 Pain VAS 0.4 0.5
 Disease activity VAS 0.5 0.5
 Well-being VAS 0.6 0.7
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.84 for PF-LL, 0.92 for PF-HW, 
0.88 for PF-US. Cronbach’s alpha was 0.91 for HRQoL 
PhH and 0.91 for HRQoL PsH.
Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in ten JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 7 days (1–7 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed an almost 
perfect reproducibility (ICC = 0.97). The ICC for the 
HRQoL PhH and for the HRQoL PsH scores showed an 
almost perfect reproducibility (ICC = 0.99 and ICC = 1.0, 
respectively).
Convergent validity
The Spearman’s correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.6 to 0.8 
(median = 0.6). The PF total score best correlation was 
observed with the parent’s assessment of disease activity 
(r = 0.8, p < 0.001). For the HRQoL, the median correla-
tion of the PhH with the JIA core set of outcome variables 
ranged from 0.6 to 0.7 (median = 0.6), whereas for the PsH 
ranged from 0.2 to 0.4 (median = 0.3). The PhH showed the 
best correlation with the physician’s global assessment of 
disease activity (r = 0.7, p < 0.001) and the PsH with the 
parent global assessment of well-being (r = 0.7, p < 0.001). 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centered and laboratory measures were 0.4 (0.4–0.5), 0.5 
(0.4–0.5), 0.6 (0.5–0.7), respectively.
Discussion
In this study, the Algerian Arabic version of the JAMAR 
is the result of the local adaptation of the translation in 
Arabic performed by the PRINTO centre in Saudi Ara-
bia. According to the results of the validation analysis, the 
Algerian Arabic parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated 
well between patients with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR and the overall internal consistency was 
excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which suggests that children are equally reliable 
proxy reporters of their disease and health status as their 
parents. The JAMAR is aimed to evaluate the side effects 
of medications and school attendance, which are other 
dimensions of daily life that were not previously con-
sidered by other HRQoL tools. This may provide useful 
information for intervention and follow-up in health care.
In conclusion, the Algerian Arabic version of the 
JAMAR was found to have satisfactory psychometric 
properties and it is, thus, a reliable and valid tool for the 
multidimensional assessment of children with JIA.
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